Short answer: nobody knows.

If you've searched "Wegovy pill Australia" recently, you've probably landed on a handful of GP clinic blogs confidently predicting "late 2026" or "2027." Here's the problem: none of them cite a verified source for that date, because there isn't one. As of the most recent public statement on record, Novo Nordisk had not lodged an application with the Therapeutic Goods Administration (TGA) in Australia, for oral semaglutide at all.

This matters if you're on a GLP-1 medication, considering one, or trying to plan around what's actually available in Australia versus what's trending on US/UK social media.

What's actually happened so far

• December 2025: The FDA approved Novo Nordisk's oral semaglutide 25mg tablet (branded Wegovy) for chronic weight management in the US, based on Phase III OASIS-4 trial data.
• Same period: Novo Nordisk confirmed it had submitted the oral formulation to the EMA and "other regulatory authorities" — but it was explicitly unclear whether Australia was among them.
• TGA's on-record response: A TGA spokesperson stated plainly that the administration had not received an application for the Wegovy pill, and that the timing of any submission is a commercial decision made entirely by the sponsor (Novo Nordisk). The TGA cannot evaluate a product that hasn't been submitted, and it cannot force a company to submit one.

That's the entire factual record. Everything else you're reading is extrapolation or not the reality for Australia.

Why the "late 2026" guesses don't hold up

A few Australian GP clinic websites have published pieces stating oral semaglutide "may be available in Australia by late 2026." These aren't sourced to the TGA — they're sourced to US launch timing, which tells you nothing about the Australian regulatory queue.

For context on how the process actually works: Wegovy (the injection) was TGA-registered in February 2025, well after its original 2022 Australian approval for a different indication — regulatory timelines here consistently run behind the US and EU by a year or more, even for products already in market with an existing safety file. A brand-new dosage form still needs its own submission and evaluation cycle. Standard TGA prescription medicine evaluations typically run 12+ months from the point an application is accepted — and that clock hasn't even started.

Realistic framing: if Novo Nordisk lodges an application sometime in 2026, Australian availability is more plausibly a 2027–2028 event, not "late 2026."

What's actually available in Australia right now

For weight management, TGA-approved and available today by private prescription (not PBS-subsidised):

• Wegovy (semaglutide weekly injection) — approved for chronic weight management and, more recently, cardiovascular risk reduction in adults with established heart disease and obesity/overweight.
• Mounjaro (tirzepatide weekly injection) — approved for chronic weight management, and more recently for moderate-to-severe obstructive sleep apnoea with obesity.

Rybelsus (oral semaglutide) is also TGA-registered in Australia — but only for type 2 diabetes, not weight management. It is not the same product, dose, or indication as the Wegovy pill.

Compounded semaglutide products are not TGA-evaluated and the TGA has explicitly warned against them, including taking enforcement action against at least one compounding pharmacy for advertising them.

The bottom line

There is no confirmed timeline for the Wegovy pill in Australia because no application has been lodged. If someone tells you a specific date, ask them for the TGA source — there isn't one to give you. What exists today for TGA-approved weight management in Australia is the injectable options above, prescribed and monitored by a doctor.

This article reflects publicly available TGA statements and regulatory status as of mid-2026 and will be updated if the regulatory position changes. It is general information, not medical advice — talk to your doctor or dietitian about what's right for you.